Germany · Delayed Price · Currency is EUR Galapagos NV Company Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Country | Belgium |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 704 |
| CEO | Henry Gosebruch |
Contact Details
Address: Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium | |
| Phone | 32 1 534 29 00 |
| Website | glpg.com |
Stock Details
| Ticker Symbol | GXEA |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Henry Gosebruch | Chief Executive Officer |
| Aaron Cox | Chief Financial Officer |
| Glenn Schulman | Head of Investor Relations |